Humoral immune response for early diagnosis of breast carcinoma

S. M. Pupa, S. Forti, A. Balsari1 and S. Ménard

Molecular targeting Unit, Department of Experimental Oncology, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan; 1Institute of Pathology, University of Milan, Italy (E-mail: menard@istitutotumori.mi.it)

Mortality from cancer, in particular breast carcinomas, has decreased in the last decade, due principally to early diagnosis of the disease. A major effort to improve diagnosis further by identifying serological markers indicative of early-stage disease has met with little success, except for a few oncotypes not including breast carcinoma. Indeed, the release of tumor markers into the serum is a late event associated with a large tumor mass and thus not useful for early diagnosis [1].

In non-oncological diseases such as infectious diseases, early diagnostic tests are mainly based on the humoral immune response elicited by the infectious agent rather than on detection of the agent per se. We speculated that the presence of specific antibodies against cancer cells might precede the detection of specific markers released by the tumor. However, studies have clearly indicated that the genetic alterations responsible for the disease are potentially numerous and not all gene products are immunogenic. Recently, SEREX analysis has been used to dissect the patient’s immune response and to select numerous tumor-associated antigens [2]. As expected, none of these tumor-related molecules alone were recognized at a sufficiently high frequency or showed sufficiently restricted immunological recognition by breast cancer patient sera to be used as a diagnostic tool. Our SEREX screening of a cDNA library from a breast carcinoma cell line with a selected patient’s serum identified 14 different gene products recognized by antibodies (unpublished). Considering the frequency of antibodies in patients and age-matched healthy donors directed against five antigens with the highest tumor restriction, i.e. lactate dehydrogenase-A (LDH-A), lactate dehydrogenase-B (LDH-B), fibulin-1, thyroid hormone-binding protein (THBP) and one novel antigen, none of these immunogenic molecules can be used alone for early detection of cancer. However, when reactivity against three of these five molecules was considered positive, 15 out of 20 patients with early breast carcinoma scored positive compared with only one out of 20 healthy donors (Table 1). In these pathological sera, detection of routine breast tumor markers such as c-erbB-2, Ca15.3 and CEA was low and therefore not diagnostic. Our findings point to the promise of early disease diagnosis based on the presence of specific antibodies directed against transformation-related molecules by selecting the appropriate set of SEREX-defined antigens with the highest tumor specificity and the highest frequency of patient recognition among those in the broad array of the cancer immunome repertoire.


View this table:
[in this window]
[in a new window]
 
Table 1. Frequency of serum positivity for SEREX-defined tumor antigens in breast carcinoma patients and healthy donors
 
S. M. Pupa, S. Forti, A. Balsari & S. Ménard

Molecular targeting Unit, Department of Experimental Oncology, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan; Institute of Pathology, University of Milan, Italy (E-mail: menard@istitutotumori.mi.it)

References

1. American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on 17 May 1996 by the American Society of Clinical Oncology. J Clin Oncol 1996; 14: 2843–2877.[Abstract]

2. Old LJ, Chen YT. New paths in human cancer serology. J Exp Med 1998; 187: 1163–1167.[Free Full Text]





This Article
Full Text (PDF)
E-letters: Submit a response
Alert me when this article is cited
Alert me when E-letters are posted
Alert me if a correction is posted
Services
Email this article to a friend
Similar articles in this journal
Similar articles in ISI Web of Science
Similar articles in PubMed
Alert me to new issues of the journal
Add to My Personal Archive
Download to citation manager
Search for citing articles in:
ISI Web of Science (2)
Disclaimer
Request Permissions
Google Scholar
Articles by Pupa, S. M.
Articles by Ménard, S.
PubMed
PubMed Citation
Articles by Pupa, S. M.
Articles by Ménard, S.